Literature DB >> 2042982

Prognostic significance of paraproteinaemia in rheumatoid arthritis.

C Kelly1, G Baird, H Foster, H Hosker, I Griffiths.   

Abstract

The incidence of lymphoma and myeloma is increased in rheumatoid arthritis (RA), though the reasons for this are incompletely understood. The predictive value of monoclonal gammopathy in RA for the later development of lymphoproliferative malignancy was assessed. A serum paraprotein was discovered in 23 patients (14 female) with a median age of 58 years and a median duration of RA of six years. The paraprotein was quantified and further investigations, including a bone marrow examination and skeletal survey, were undertaken to study the possible development of a lymphoproliferative disorder. Secondary Sjögren's syndrome was noted in 12 patients. The paraprotein was monoclonal in 21 patients and was classed as IgG (12 cases), IgA (six cases), or IgM (three cases). Biclonal paraproteins were seen in two patients. Free light chains were found in the urine of eight patients. Bone marrow abnormalities were found in 13 subjects. The bone marrow was abnormal in four of six patients with an IgA paraprotein, in two of three with an IgM paraprotein but in only five of 12 patients with an IgG paraprotein. Patients were followed up for a median of four years, and five patients with an abnormal bone marrow developed myeloma, of whom three had an IgA lambda paraprotein. Two other patients developed non-Hodgkin's lymphoma. Extra-articular bone erosions were seen in four patients, three of whom developed myeloma, but the presence of urinary free light chains was not specific for the development of malignancy. Paraproteinaemia in RA indicates monoclonal B cell proliferation and carries a high risk of malignant transformation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2042982      PMCID: PMC1004412          DOI: 10.1136/ard.50.5.290

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  24 in total

1.  THE DEVELOPMENT OF MALIGNANT LYMPHOMA IN THE COURSE OF SJOEGREN'S SYNDROME.

Authors:  N TALAL; J J BUNIM
Journal:  Am J Med       Date:  1964-04       Impact factor: 4.965

2.  Rheumatoid arthritis and plasmacytomatosis.

Authors:  T GALLI; E CHITI
Journal:  Ann Rheum Dis       Date:  1955-09       Impact factor: 19.103

3.  Mortality among arthritics.

Authors:  R R Monson; A P Hall
Journal:  J Chronic Dis       Date:  1976-07

Review 4.  Neoplasia in rheumatoid arthritis.

Authors:  D P Symmons
Journal:  J Rheumatol       Date:  1988-09       Impact factor: 4.666

5.  Rheumatoid arthritis, dysproteinemic arthropathy, and paraproteinemia.

Authors:  Z A Zawadzki; T G Benedek
Journal:  Arthritis Rheum       Date:  1969-12

6.  Rheumatoid arthritis terminating in plasmocytoma.

Authors:  O Wegelius; B Skrifvars; L Andersson
Journal:  Acta Med Scand       Date:  1970 Jan-Feb

7.  The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up.

Authors:  J A Baltus; J W Boersma; A P Hartman; J P Vandenbroucke
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

8.  Monitoring immunocytoma.

Authors:  J R Hobbs
Journal:  Minerva Med       Date:  1978-08-04       Impact factor: 4.806

9.  The association of rheumatoid arthritis with plasma cell and lymphocytic neoplasms.

Authors:  G J Goldenberg; F Paraskevas; L G Israels
Journal:  Arthritis Rheum       Date:  1969-12

10.  Lymphoid neoplasia following connective tissue disease.

Authors:  P M Banks; G A Witrak; D L Conn
Journal:  Mayo Clin Proc       Date:  1979-02       Impact factor: 7.616

View more
  5 in total

1.  Light chain multiple myeloma in a patient with long-standing rheumatoid arthritis.

Authors:  Alexandra Alexopoulou; Spyros P Dourakis; Alexandra Apostolopoulou; Anna Kandyli; Helen Pandelidaki; Athanasios J Archimandritis
Journal:  Clin Rheumatol       Date:  2005-04-23       Impact factor: 2.980

Review 2.  Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis: a case report and review of literature.

Authors:  Yasunobu Sekiguchi; Asami Shimada; Kunimoto Ichikawa; Mutsumi Wakabayashi; Keiji Sugimoto; Keigo Ikeda; Iwao Sekikawa; Shigeki Tomita; Hiroshi Izumi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ohta; Norio Komatsu; Masaaki Noguchi
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 3.  [Gastrointestinal tumors. Clinical manifestations of paraneoplastic rheumatic symptoms].

Authors:  W-J Mayet
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

4.  Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis.

Authors:  Xiaoli Deng; Cynthia S Crowson; S Vincent Rajkumar; Angela Dispenzieri; Dirk R Larson; Terry M Therneau; Eric L Matteson; Robert A Kyle; Jerry A Katzmann; Sherine E Gabriel; John M Davis
Journal:  J Rheumatol       Date:  2015-01-15       Impact factor: 4.666

5.  Systemic lupus Erythematosus and IgA multiple myeloma: a rare association?

Authors:  J Bila; N Suvajdzic; I Elezovic; M Colovic; D Boskovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.